person
Belen R. V.
- Country
- Spain
- Department
- Oncología
Research Overview
assignment
24
Clinical Trials ·
- Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study
- A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
- Phase 2 Study of Pembrolizumab, MK-1084, and Combination Therapy in Patients With Advanced or Metastatic KRAS G12C-Mutant Nonsquamous Non-Small Cell Lung Cancer
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
211
Sites with multiple studies
Has run more than one trial at 211 of 447 partner sites.
Specializations
Lung Cancer Research
Specializes in advanced treatment approaches for non-small cell lung cancer (NSCLC), with particular emphasis on novel immunotherapy combinations and targeted therapies for both early-stage and metastatic disease.
- Stage II-IIIB NSCLC treatment protocols
- EGFR mutation-positive therapies
- Immunotherapy combinations
Melanoma Studies
Conducts research in advanced melanoma treatment, focusing on innovative immunotherapy approaches for both cutaneous and mucosal variants.
- Combination immunotherapy strategies
- Novel therapeutic agents
- Treatment of advanced disease
Head and Neck Cancer
Investigates treatment options for squamous cell carcinoma of the head and neck, with specific focus on immunotherapy combinations for recurrent and metastatic disease.
- PD-L1 positive cancers
- First-line treatment protocols
- Novel combination approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.